Literature DB >> 24460473

In vitro-in vivo correlation of the effect of supersaturation on the intestinal absorption of BCS Class 2 drugs.

Haruki Higashino1, Tsubasa Hasegawa, Mari Yamamoto, Rie Matsui, Yoshie Masaoka, Makoto Kataoka, Shinji Sakuma, Shinji Yamashita.   

Abstract

The aim of this study was to establish an in vitro method for evaluating the effect of supersaturation on oral absorption of poorly water-soluble drugs in vivo. Albendazole, dipyridamole, gefitinib, and ketoconazole were used as model drugs. Supersaturation of each drug was induced by diluting its stock solution by fasted state simulated intestinal fluid (FaSSIF) (solvent-shift method), then dissolution and precipitation profile of the drug was observed in vitro. The crystalline form of the precipitate was checked by differential scanning calorimetry (DSC). For comparison, control suspension was prepared by suspending a drug powder directly into FaSSIF (powder-suspending method). In vivo intestinal absorption of the drug was observed in rats by determined the plasma concentration after intraduodenal administration of drug suspensions. For all drugs, suspensions prepared by solvent-shift method showed significantly higher dissolved concentration in vitro than that prepared by powder-suspending method, clearly indicated the induction of supersaturation. DSC analysis revealed that crystalline form of the precipitate profoundly affects the extent and the duration of supersaturation. A rat in vivo study confirmed that the supersaturation of these drugs increased the fraction absorbed from the intestine, which corresponded well to the in vitro dissolution and precipitation profile of drugs except for ketoconazole. For ketoconazole, an in vivo absorption study was performed in rats pretreated with 1-aminobenzotriazole, a potent inhibitor of CYP mediated metabolism. CYP inhibition study suggested that the high luminal concentration of ketoconazole caused by supersaturation saturated the metabolic enzymes and further increased the systemic exposure of the absorbed drug. The additional effects of supersaturation on the absorption of ketoconazole are consistent with previous studies in humans under differing gastric pH conditions. In conclusion, effects of supersaturation on the intestinal absorption of poorly water-soluble drugs could be predicted from in vitro dissolution and a precipitation study. However if supersaturation affects the pharmacokinetic profiles of drugs, such as a first-pass metabolism, a combination with in vivo study should be required to evaluate its impact on oral bioavailability.

Entities:  

Keywords:  in vitro−in vivo correlation; oral drug absorption; poorly water-soluble drugs; supersaturation

Mesh:

Substances:

Year:  2014        PMID: 24460473     DOI: 10.1021/mp400465p

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  5 in total

1.  Role of Self-Association and Supersaturation in Oral Absorption of a Poorly Soluble Weakly Basic Drug.

Authors:  Ajit S Narang; Sherif Badawy; Qingmei Ye; Dhaval Patel; Maria Vincent; Krishnaswamy Raghavan; Yande Huang; Aaron Yamniuk; Balvinder Vig; John Crison; George Derbin; Yan Xu; Antonio Ramirez; Michael Galella; Frank A Rinaldi
Journal:  Pharm Res       Date:  2015-02-28       Impact factor: 4.200

2.  Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis.

Authors:  Michael Thomas; Stephen Brand; Manu De Rycker; Fabio Zuccotto; Iva Lukac; Peter G Dodd; Eun-Jung Ko; Sujatha Manthri; Kate McGonagle; Maria Osuna-Cabello; Jennifer Riley; Caterina Pont; Frederick Simeons; Laste Stojanovski; John Thomas; Stephen Thompson; Elisabet Viayna; Jose M Fiandor; Julio Martin; Paul G Wyatt; Timothy J Miles; Kevin D Read; Maria Marco; Ian H Gilbert
Journal:  J Med Chem       Date:  2021-04-27       Impact factor: 7.446

Review 3.  Recent advances in improving oral drug bioavailability by cocrystals.

Authors:  Shahram Emami; Mohammadreza Siahi-Shadbad; Khosro Adibkia; Mohammad Barzegar-Jalali
Journal:  Bioimpacts       Date:  2018-05-31

4.  Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.

Authors:  Advait Nagle; Agnes Biggart; Celine Be; Honnappa Srinivas; Andreas Hein; Diana Caridha; Richard J Sciotti; Brandon Pybus; Mara Kreishman-Deitrick; Badry Bursulaya; Yin H Lai; Mu-Yun Gao; Fang Liang; Casey J N Mathison; Xiaodong Liu; Vince Yeh; Jeffrey Smith; Isabelle Lerario; Yongping Xie; Donatella Chianelli; Michael Gibney; Ashley Berman; Yen-Liang Chen; Jan Jiricek; Lauren C Davis; Xianzhong Liu; Jaime Ballard; Shilpi Khare; Fabian Kurt Eggimann; Alexandre Luneau; Todd Groessl; Michael Shapiro; Wendy Richmond; Kevin Johnson; Patrick J Rudewicz; Srinivasa P S Rao; Christopher Thompson; Tove Tuntland; Glen Spraggon; Richard J Glynne; Frantisek Supek; Christian Wiesmann; Valentina Molteni
Journal:  J Med Chem       Date:  2020-07-29       Impact factor: 7.446

Review 5.  Stabilizing Agents for Drug Nanocrystals: Effect on Bioavailability.

Authors:  Annika Tuomela; Jouni Hirvonen; Leena Peltonen
Journal:  Pharmaceutics       Date:  2016-05-20       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.